A Phase I Study of BIIB015, a Humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2015
At a glance
- Drugs BIIB 015 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Biogen
- 25 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 12 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.